



Cohere Medical Policy – Computed Tomography (CT), Orbit/Ear/Sella

Clinical Guidelines for Medical Necessity Review

Version: 3
Effective Date: October 30, 2024

Important Notices

Notices & Disclaimers:

GUIDELINES ARE SOLELY FOR COHERE'S USE IN PERFORMING MEDICAL NECESSITY REVIEWS AND ARE NOT INTENDED TO INFORM OR ALTER CLINICAL DECISION-MAKING OF END USERS.

Cohere Health, Inc. ("**Cohere**") has published these clinical guidelines to determine the medical necessity of services (the "**Guidelines**") for informational purposes only, and solely for use by Cohere's authorized "**End Users**". These Guidelines (and any attachments or linked third-party content) are not intended to be a substitute for medical advice, diagnosis, or treatment directed by an appropriately licensed healthcare professional. These Guidelines are not in any way intended to support clinical decision-making of any kind; their sole purpose and intended use is to summarize certain criteria Cohere may use when reviewing the medical necessity of any service requests submitted to Cohere by End Users. Always seek the advice of a qualified healthcare professional regarding any medical questions, treatment decisions, or other clinical guidance. The Guidelines, including any attachments or linked content, are subject to change at any time without notice.

©2024 Cohere Health, Inc. All Rights Reserved.

Other Notices:

HCPCS® and CPT® copyright 2024 American Medical Association. All rights reserved.

Fee schedules, relative value units, conversion factors and/or related components are not assigned by the AMA, are not part of CPT, and the AMA is not recommending their use. The AMA does not directly or indirectly practice medicine or dispense medical services. The AMA assumes no liability for data contained or not contained herein.

HCPCS and CPT are registered trademarks of the American Medical Association.

Guideline Information:

Specialty Area: Diagnostic Imaging

Guideline Name: Cohere Medical Policy - Computed Tomography (CT), Orbit/Ear/Fossa

Date of last literature review: 8/20/2024

Document last updated: 10/30/2024

Type: Adult (18+ yo) | Pediatric (0-17 yo)

Table of Contents

Important Notices	2
Table of Contents	3
Medical Necessity Criteria	4
Service: Computed Tomography (CT), Orbit/Ear/Sella	4
Recommended Clinical Approach	4
Medical Necessity Criteria	4
Non-Indications	8
Disclaimer on Radiation Exposure in Pediatric Population	8
Level of Care Criteria	9
Procedure Codes (CPT/HCPCS)	9
Medical Evidence	10
References	11
Clinical Guideline Revision History/Information	13

Medical Necessity Criteria

Service: Computed Tomography (CT), Orbit/Ear/Sella

Recommended Clinical Approach

Computed tomography (CT) is often the first-line imaging exam for many disorders of the extra-cranial head due to its speed, availability, and high resolution. In the setting of trauma and other primary osseous abnormalities, contrast is not routinely employed. For many, soft-tissue processes, contrast will be preferred. The specific area imaged, reformations performed, and radiation dose will depend upon the clinical question being addressed and deferred to the supervising radiologist.¹

Medical Necessity Criteria

→ **Computed tomography (CT), orbit/ear/fossa** is considered appropriate if **ANY** of the following is **TRUE**¹:

◆ Orbital indications, including **ANY** of the following:

- Trauma-related conditions, including traumatic visual defect with suspected orbital injury²; **OR**
- **ANY** of the following if MRI is contraindicated or cannot be performed:
 - Congenital conditions (e.g. capillary hemangioma, optic nerve hypoplasia); **OR**
 - Optic neuritis; **OR**
 - Eye pain, with history or other sign or symptom, indicating non-ischemic pathology; **OR**
 - Ophthalmoplegia; **OR**
 - Eye movement abnormality in a child (e.g., strabismus, nystagmus in a child 6 months or older); **OR**
 - Vision loss or visual field deficit with history or other signs or symptoms indicating non-ischemic intra-orbital pathology; **OR**
- Conditions, known or suspected, including **ANY** of the following²:
 - Initial staging, treatment response, surveillance, complication, recurrence, treatment planning, or

- treatment response of an orbital mass (e.g., dermoid, melanoma, lymphoma, metastases)³; **OR**
- Orbital pseudotumor or orbital inflammatory disease; **OR**
- Osseous lesions (e.g., fibrodysplasia, Paget's); **OR**
- Foreign-body, suspected clinically or seen on prior imaging; **OR**
- Orbital infectious process, suspected or known, that has failed medical management (e.g. orbital cellulitis not responding appropriately to antibiotics) or patient is pediatric or immunocompromised; **OR**
- Scleritis confirmed clinically with failure of medical management or with complication suspected⁴; **OR**
- Uveitis, confirmed clinically with complication suspected; **OR**
- Thyroid orbitopathy; **OR**
- Venous conditions (e.g., orbital varices); **OR**
- Additional evaluation is needed when etiology remains unclear following a complete eye examination that includes funduscopy, including **ANY** of the following:
 - Diplopia; **OR**
 - Enophthalmos⁵; **OR**
 - Exophthalmos; **OR**
 - Orbital asymmetry; **OR**
 - Preseptal or post-septal orbital mass, otherwise unexplained; **OR**
 - Proptosis; **OR**
 - Unilateral papilledema; **OR**
 - Orbital hemorrhage; **OR**
- Preoperative, postoperative, or pre-treatment evaluation for surgery, radiation, or chemotherapy; **OR**
- ◆ Temporal bone and inner ear indications including **ANY** of the following:
 - Conditions, known or suspected, including **ANY** of the following⁶; **OR**
 - Aberrant and symptomatic congenital or acquired anatomy (e.g., stenosis of the EAC or dehiscence of the superior semicircular canal, facial nerve canal, carotid canal, or jugular bulb); **OR**

- Cholesteatoma, initial and 9 to 12-month postoperative follow-up; **OR**
- Tympanosclerosis; **OR**
- Neoplastic conditions, detection, and follow-up (including tumors of the internal or external auditory canal, inner ear, and mastoid); **OR**
- Otitis media, recurrent with at least 3 episodes in the past 12 months, with complications suspected (e.g. hearing loss, intracranial extension, mastoiditis)⁷; **OR**
- Malignant otitis externa, unresponsive to antibiotics; **OR**
- Mastoiditis; **OR**
- Other infectious processes involving the middle or inner ear, where imaging is needed to direct appropriate management; **OR**
- Bell's palsy or other facial nerve abnormalities requiring evaluation of the extracranial portion of the nerve (MRI is contraindicated or cannot be performed); **OR**
- Tinnitus, unexplained by history or physical examination, and is worsening or affects daily function (MRI is contraindicated or cannot be performed)⁸; **OR**
- Symptoms or signs evaluated by complete auditory examination, including **ANY** of the following⁶:
 - Conductive, mixed-conductive, or congenital hearing loss; **OR**
 - Sensorineural hearing loss, acquired or congenital, (MRI is contraindicated or cannot be performed); **OR**
 - Total deafness, otherwise unexplained; **OR**
 - Vertigo, unexplained by history or physical examination with **ANY** of the following:
 - ◆ Worsening; **OR**
 - ◆ Affects daily function; **OR**
 - ◆ Associated hearing loss or other neurological deficits; **OR**
 - ◆ History of prior infection (e.g., otitis or meningitis); **OR**
 - ◆ History of prior trauma; **OR**

- Trauma-related conditions related to the ear, including evaluation of cerebrospinal fluid leak⁸⁻¹⁰; **OR**
 - Preoperative, postoperative, or pre-treatment evaluation for surgery, radiation, or chemotherapy (including evaluation for cochlear implant); **OR**
 - Vascular conditions, known or suspected, related to the ear or temporal bone, including evaluation of pulsatile tinnitus¹¹; **OR**
- ◆ Sellar and posterior fossa indications, including **ANY** of the following indications related to a sella or posterior fossa:
- Sellar mass (including pituitary masses) is suspected due to documented clinical or laboratory findings (e.g., prolactinemia); **OR**
 - Visual field deficit (e.g., bitemporal hemianopsia) indicating optic nerve compression; **OR**
 - Other neoplastic conditions, known, suspected, or suggested by prior imaging (e.g., meningioma); **OR**
 - Trauma-related conditions; **OR**
 - Pituitary dysfunction, suggested by documented laboratory or clinical abnormalities (e.g., pituitary failure due to conditions such as pituitary apoplexy); **OR**
 - Vascular conditions, known or suspected, including aberrant anatomy; **OR**
 - Preoperative, postoperative, or pre-treatment evaluation for surgery, radiation, or chemotherapy (including pre-operative planning for removal of the pituitary tumor); **OR**
- ◆ Repeat imaging (defined as repeat request following recent imaging of the same anatomic region with the same modality), in the absence of established guidelines, will be considered reasonable and necessary if **ANY** of the following is **TRUE**:
- New or worsening symptoms, such that repeat imaging would influence treatment; **OR**
 - One-time clarifying follow-up of a prior indeterminate finding; **OR**
 - In the absence of change in symptoms, there is an established need for monitoring which would influence management.

Non-Indications

→ **Computed tomography (CT), orbit/ear/fossa** with contrast is not considered appropriate if **ANY** of the following is **TRUE** if contrast is used¹²:

- ◆ The patient has undergone advanced imaging of the same body part within 3 months without undergoing treatment or developing new or worsening symptoms¹⁸; **OR**
- ◆ If contrast is used, history of anaphylactic allergic reaction to iodinated contrast media.

*NOTE: The referring professional and radiologist should discuss the risks and benefits of contrast media administration, including possible prophylaxis, in patients with chronic or worsening kidney disease or severe renal failure.

**NOTE: CT in pregnant patients should be requested at the discretion of the ordering provider and obstetric care provider.

***NOTE: CT in patients with claustrophobia should be requested at the discretion of the ordering provider.

Disclaimer on Radiation Exposure in Pediatric Population

Due to the heightened sensitivity of pediatric patients to ionizing radiation, minimizing exposure is paramount. At Cohere, we are dedicated to ensuring that every patient, including the pediatric population, has access to appropriate imaging following accepted guidelines. Radiation risk is dependent mainly on the patient's age at exposure, the organs exposed, and the patient's sex, though there are other variables. The following technical guidelines are provided to ensure safe and effective imaging practices:

Radiation Dose Optimization: Adhere to the lowest effective dose principle for pediatric imaging. Ensure that imaging protocols are specifically tailored for pediatric patients to limit radiation exposure.¹³⁻¹⁴

Alternative Modalities: Prioritize non-ionizing imaging options such as ultrasound or MRI when clinically feasible, as they are less likely to expose the patient to ionizing radiation. For instance, MRI or ultrasound should be considered if they are more likely to provide an accurate diagnosis than CT, fluoroscopy, or radiography.¹³⁻¹⁴

Cumulative Dose Monitoring: Implement systems to track cumulative radiation exposure in pediatric patients, particularly for those requiring

multiple imaging studies. Regularly reassess the necessity of repeat imaging based on clinical evaluation.¹³⁻¹⁴

CT Imaging Considerations: When CT is deemed the best method for achieving a correct diagnosis, use the lowest possible radiation dose that still yields reliable diagnostic images.¹³⁻¹⁴

Cohere Imaging Gently Guideline

The purpose of this guideline is to act as a potential override when clinically indicated to adhere to Imaging Gently and Imaging Wisely guidelines and As Low As Reasonably Possible (ALARA) principles.

Level of Care Criteria

Inpatient or Outpatient

Procedure Codes (CPT/HCPCS)

CPT/HCPCS Code	Code Description
70480	Computed tomography (CT), orbit, sella, or posterior fossa or outer, middle, or inner ear; without contrast material
70481	Computed tomography (CT), orbit, sella, or posterior fossa; with contrast material(s)
70482	Computed tomography (CT), orbit, sella, or posterior fossa; without contrast material, followed by contrast material(s) and further sections
76380	Computed tomography, limited or localized follow-up study

Medical Evidence

Bedernik et al. (2022) conducted a randomized control trial (RCT) to assess image quality by comparing single-energy computed tomography (SECT) with automated tube voltage adaptation (TVA) to dual-energy CT (DECT) weighted average images. A total of 80 patients underwent SECT or radiation dose-matched DECT. The effective radiation dose (ED) showed no significant difference between the SECT and DECT study groups. Compared to the SECT group, the DECT group exhibited significantly higher contrast-to-noise ratio differences (CNRD) for jugular veins relative to fatty tissue and muscle tissue relative to fatty tissue. However, the CNRD for jugular veins relative to muscle tissue was comparable between groups. Image artifacts were also less pronounced, and overall diagnostic acceptability was higher in the DECT group. Overall, DECT-weighted average images demonstrate superior objective and subjective image quality compared to SECT performed with TVA in head and neck imaging.¹⁵

Smith-Bindman et al. (2020) performed an RCT to study the efficacy of interventions to lower the amount of radiation exposure. The RCT included 864,080 adults at 100 facilities who underwent a CT scan, including CT Head (n = 1,156,657 scans). The study included two primary measures: the percentage of high-dose CT scans and the average effective dose administered at the facility level. The study's secondary measure included the doses received by specific organs - outcomes assessed for the impact of the interventions and outcomes post-intervention. Data were contrasted with pre-intervention data, utilizing hierarchical generalized linear models that accounted for temporal patterns and patient attributes. In conclusion, data regarding CT radiation dosage and practical recommendations may improve quality, including significant dose reductions, especially for organ-specific doses.¹⁶

Aulino et al. (2018) reported on a clinical trial that focused on an assessment tool for the late effect continuum of lymphedema and fibrosis (LEF) for patients with head and neck cancer (HNC) undergoing CT. The tool evaluates areas of soft tissue damage resulting from tumors, surgical interventions, or radiation therapy. The tool analyzed CT scans taken before and after treatment in 10 patients with HNC. The finalized tool has 11 elements, including assessing fat stranding at six specific sites, measuring epiglottic thickness, and measuring prevertebral soft tissue thickness at C3. The trial includes 176 CT scans from 20 patients (with a range of 4-14 scans per patient). The final version of the LEF assessment tool (CT-LEFAT) offers a standardized approach to assess critical sites affected by soft tissue damage. Studies continue to evaluate reliability and validity.¹⁷

References

1. American College of Radiology (ACR), American Society of Neuroradiology (ASNR), Society for Pediatric Radiology (SPR). ACR-ASNR-SPR practice parameter for the performance of computed tomography (CT) of the extracranial head and neck - resolution 5. Updated 2021. Accessed August 14, 2024. <https://www.acr.org/-/media/ACR/Files/Practice-Parameters/CT-Head-Neck.pdf>.
2. Expert Panel on Neurologic Imaging, Kennedy TA, Corey AS, et al. ACR appropriateness criteria - orbits, vision, and visual loss. *J Am Coll Radiol*. 2018 May;15(5S):S116-S131. doi: 10.1016/j.jacr.2018.03.023. PMID: 29724415.
3. Expert Panel on Neurological Imaging, Gule-Monroe MK, Calle S, et al. ACR appropriateness criteria - staging and post-therapy assessment of head and neck cancer. *J Am Coll Radiol*. 2023 Nov;20(11S):S521-S564. doi: 10.1016/j.jacr.2023.08.008. PMID: 38040469.
4. Diogo MC, Jager MJ, Ferreira TA. CT and MR Imaging in the Diagnosis of Scleritis. *AJNR Am J Neuroradiol*. 2016 Dec;37(12):2334-2339. doi: 10.3174/ajnr.A4890. Epub 2016 Jul 21. PMID: 27444937; PMCID: PMC7963878.
5. Boyette JR, Pemberton JD, Bonilla-Velez J. Management of orbital fractures: Challenges and solutions. *Clin Ophthalmol*. 2015 Nov 17;9:2127-37. doi: 10.2147/OPHTH.S80463. PMID: 26604678; PMCID: PMC4655944.
6. Expert Panel on Neurologic Imaging, Sharma A, Kirsch CFE, et al. ACR appropriateness criteria - hearing loss and/or vertigo. Published 2018. Accessed January 17, 2024. <https://acsearch.acr.org/docs/69488/Narrative/>.
7. Ramakrishnan K, Sparks RA, Berryhill WE. Diagnosis and treatment of otitis media. *Am Fam Physician*. 2007 Dec 1;76(11):1650-8. PMID: 18092706.
8. Expert Panel on Neurological Imaging, Shih RY, Burns J, et al. ACR appropriateness criteria - head trauma: 2021 update. *J Am Coll Radiol*. 2021 May;18(5S):S13-S36. doi: 10.1016/j.jacr.2021.01.006. PMID: 33958108.
9. Expert Panel on Major Trauma Imaging, Shyu JY, Khurana B, et al. ACR appropriateness criteria - major blunt trauma. *J Am Coll Radiol*. 2020 May;17(5S):S160-S174. doi: 10.1016/j.jacr.2020.01.024. PMID: 32370960.
10. Expert Panel on Neurological Imaging, Parsons MS, Policeni B, et al. ACR appropriateness criteria - imaging of facial trauma following primary survey. *J Am Coll Radiol*. 2022 May;19(5S):S67-S86. doi: 10.1016/j.jacr.2022.02.013. PMID: 35550806.
11. Expert Panel on Neurologic Imaging, Ledbetter LN, Burns J, et al. ACR appropriateness criteria - cerebrovascular diseases, aneurysm, vascular malformation, and subarachnoid hemorrhage. *J Am Coll*

- Radiol.* 2021 Nov;18(11S):S283–S304. doi: 10.1016/j.jacr.2021.08.012. PMID: 34794589.
12. Davenport MS, Perazella MA, Yee J, et al. Use of intravenous iodinated contrast media in patients with kidney disease: Consensus statements from the American College of Radiology and the National Kidney Foundation. *Radiology.* 2020;294(3):660–668. doi: 10.1148/radiol.2019192094. PMID: 33015613; PMCID: PMC7525144.
 13. The Image Gently Alliance. Procedures – image gently and CT scans. Updated 2014. Accessed June 26, 2024. <https://www.imagegently.org/Procedures/Computed-Tomography>.
 14. National Cancer Institute. Radiation risks and pediatric computed tomography (CT): A guide for health care. Updated September 4, 2018. Accessed June 26, 2024. <https://www.cancer.gov/about-cancer/causes-prevention/risk/radiation/pediatric-ct-scans>.
 15. Bedernik A, Wuest W, May MS, et al. Image quality comparison of single-energy and dual-energy computed tomography for head and neck patients: A prospective randomized study. *Eur Radiol.* 2022 Nov;32(11):7700–7709. doi: 10.1007/s00330-022-08689-4. PMID: 35441839; PMCID: PMC9668949.
 16. Smith-Bindman R, Chu P, Wang Y, et al. Comparison of the effectiveness of single-component and multicomponent interventions for reducing radiation doses in patients undergoing computed tomography: A randomized clinical trial. *JAMA Intern Med.* 2020 May 1;180(5):666–675. doi: 10.1001/jamainternmed.2020.0064. PMID: 32227142; PMCID: PMC7105953.
 17. Aulino JM, Wulff-Burchfield EM, Dietrich MS, et al. Evaluation of CT changes in the head and neck after cancer treatment: Development of a measurement tool. *Lymphat Res Biol.* 2018 Feb;16(1):69–74. doi: 10.1089/lrb.2017.0024. PMID: 29432066; PMCID: PMC5810430.
 18. Wasser EJ, Prevedello LM, Sodickson A, Mar W, Khorasani R. Impact of a real-time computerized duplicate alert system on the utilization of computed tomography. *JAMA Intern Med.* 2013;173(11):1024–1026. doi: 10.1001/jamainternmed.2013.543. PMID: 23609029.

Clinical Guideline Revision History/Information

Original Date: May 6, 2022		
Review History		
Version 2	8/20/2024	Annual review and policy restructure.
Version 3	10/30/2024	Edited repeat imaging criteria language.